Piramal Pharma Limited Annual Report FY2026
Piramal Pharma Limited Annual Report FY2026
Quality Scores
Latest Quarterly Earnings Summary
Loading latest quarter…
AI Summary
Piramal Pharma Limited (PPL) is an integrated pharmaceutical player specializing in CDMO, Complex Hospital Generics, and Consumer Healthcare. Since its demerger from Piramal Enterprises, the company has struggled with operational volatility and margin contraction, though revenue has grown at a modest 7% CAGR over 5 years. The business model is high-quality, serving regulated markets like the US and Europe, but the financials reflect a period of heavy reinvestment and debt-fueled growth. Asset turns remain low as the company digests significant CAPEX into its CDMO and manufacturing sites.…
Key Changes in FY2026
The business has undergone a massive structural transformation from a domestic formulation player to a global niche specialist in CDMO and Hospital Generics. Following the 2010 sale of its domestic business to Abbott, PPL has aggressively built a global footprint with 15 manufacturing sites and over 500 CDMO customers. The evolution is characterized by moving up the value chain into 'Integrated Projects,' which now represent 40% of the new order book. The PCH segment is successfully diversifying from traditional OTC into e-commerce and modern retail, reaching over 3 lakh chemists and cosmetics shops. Strategic focus has shifted from simple manufacturing to complex chemistry and differentiated critical care products like Sevoflurane and Baclofen. However, the financial results have yet to…
Management Commentary
The management, led by the Piramal family, maintains a high level of transparency and clear strategic communication through detailed investor presentations and concalls. They have successfully established PPL as a top-3 CDMO player in India and a global top-15 contender. However, there is a visible gap between the 'vision' of high-margin growth and the 'reality' of bottom-line volatility. Management has demonstrated resilience by navigating regulatory hurdles, such as the Dahej site closure revocation. The focus on integrated projects (40% of new FY24 orders) shows a strategic move toward stickier, higher-value customer relationships.
Financial Highlights
PPL's financial profile is characterized by stagnant to declining profitability despite steady revenue growth from INR 6,315 Cr in FY21 to INR 8,171 Cr in FY24. OPM dropped sharply from 23% in FY21 to 9% in FY23 before recovering to 15% in FY24, indicating high sensitivity to operating leverage and raw material costs. Profit Before Tax has fluctuated wildly, falling into negative territory in FY23 and FY26, suggesting significant non-operational drags or high fixed costs. The high tax percentage noted in recent years indicates that losses in certain jurisdictions cannot be fully offset, further dampening Net Profit. Interest costs have more than doubled since FY21, now eating a substantial portion of operating profits.
Major Opportunities
- Top 3 CDMO player in India
- 13th largest CDMO globally
- High share (84%) from regulated markets (US/EU/Japan)
Major Risks
- Net Loss reported in FY23 and FY26
- Significant operating margin compression over 5 years
- Extremely high inventory days (345 days in FY26)
About This Annual Report
The Piramal Pharma Limited FY2026 Annual Report is the company's flagship annual disclosure, filed with NSE / BSE. It covers the full-year business review, management discussion & analysis (MD&A), audited financial statements, director's report, corporate governance report, auditor's report, risk factors, capital allocation, subsidiaries, related-party transactions and ESG initiatives. This page consolidates the official PDF and an AI-generated summary so investors can quickly grasp what changed vs. prior years — sales growth, margin trend, cash flow quality, capex, dividends and management outlook — without having to read the entire filing.
Why Use AI?
- Summarises hundreds of pages into a focused executive briefing
- Identifies year-on-year key changes automatically
- Extracts management commentary and tone
- Highlights top risks and opportunities
- Compares business evolution vs. earlier years
- Answers your questions in plain English via Ask AI
Frequently Asked Questions
Related Research
AI Top Insights — Premium
Unlock deeper AI Top Insights, advanced comparisons, downloadable reports and premium features.